{"drugs":["ActHIB","Haemophilus B Conjugate Vaccine","Hiberix","Hibtiter","Pedvaxhib"],"mono":{"0":{"id":"268045-s-0","title":"Generic Names","mono":"Haemophilus B Conjugate Vaccine"},"1":{"id":"268045-s-1","title":"Dosing and Indications","sub":{"0":{"id":"268045-s-1-4","title":"Adult Dosing","mono":"<ul><li>PedvaxHB(R) not recommended for use in the adult population<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> unvaccinated patients with functional or anatomic asplenia, sickle cell disease, or undergoing elective splenectomy: 1 dose IM<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> recipients of a hematopoietic stem cell transplant: 3-dose series IM to start 6 to 12 months after successful transplant; allow 4 weeks between doses<\/li><\/ul>"},"1":{"id":"268045-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>usual dose:<\/b> 2- or 3-dose primary series plus a booster dose at 12 to 15 months of age; for catch-up immunization, the number of doses depends on age of first vaccination and product used<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> ActHIB(R), 3-dose primary series IM at age 2, 4, and 6 months; booster at 15 to 18 months of age<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> PedvaxHIB(R),2-dose primary series IM; at age 2 and 4 months; booster at 12 to 15 months of age<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (Hiberix(R); previously vaccinated, 15 to 59 months of age) booster dose, 1 dose IM<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (ActHIB(R); previously unvaccinated, 7 to 11 months of age) 2 doses IM AND booster dose at 15 to 18 months of age; doses must be separated by 2 months<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (ActHIB(R); previously unvaccinated, 12 to 14 months of age) 1 dose IM AND booster dose at 15 to 18 months of age; doses must be separated by 2 months<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (ActHIB(R); previously unvaccinated, 15 months through 5 years) 1 dose IM<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (PedvaxHIB(R); previously unvaccinated, 2 to 10 months of age) 2 doses IM AND booster dose at 12 to 15 months of age; doses must be separated by 2 months<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (PedvaxHIB(R); previously unvaccinated, 11 to 14 months of age) 2 doses IM; doses must be separated by 2 months<\/li><li><b>Invasive hemophilus influenzae type B infection; Prophylaxis:<\/b> (PedvaxHIB(R); previously unvaccinated, 15 to 71 months of age) 1 dose IM<\/li><\/ul>"},"3":{"id":"268045-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Invasive hemophilus influenzae type B infection; Prophylaxis<br\/>"}}},"3":{"id":"268045-s-3","title":"Contraindications\/Warnings","sub":[{"id":"268045-s-3-9","title":"Contraindications","mono":"<ul><li>age less than 6 weeks<\/li><li>ActHIB(R): history of hypersensitivity to any vaccine component or to any component of whole-cell diphtheria toxoid\/tetanus toxoid\/pertussis vaccine or Tripedia(R) when combined by reconstitution<\/li><li>Hiberix(R): severe allergic reaction (eg, anaphylaxis) following any previous haemophilus influenzae type b, or tetanus toxoid-containing vaccine or any vaccine component<\/li><li>PedvaxHIB(R): hypersensitivity to a previous dose, to any component of the vaccine or the diluent, or symptoms suggestive of hypersensitivity<\/li><\/ul>"},{"id":"268045-s-3-10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>adults and children greater than 6 years of age; not recommended due to low risk of Haemophilus influenza B illness<\/li><li>antigenuria occurs; urine antigen detection may not have diagnostic value within 1  to 2 weeks after vaccination<\/li><li>Guillain-Barre syndrome, history of within 6 weeks of previous tetanus toxoid-containing vaccination; carefully consider the benefits and possible risks of any tetanus toxoid-containing vaccine<\/li><li>hypersensitivity reaction, including anaphylaxis may occur<\/li><li>IM administration only; avoid injecting into a blood vessel<\/li><li>immunosuppressed children; immune response to vaccine may be suboptimal<\/li><li>latex sensitivity; tip cap, rubber plunger, and\/or vial stopper may contain natural latex rubber<\/li><li>report suspected adverse reactions to VAERS at 1-800-822-7967 or www.vaers.hhs.gov.<\/li><\/ul>"},{"id":"268045-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Haemophilus B Vaccine: C (FDA)<\/li><li>Haemophilus B Vaccine: B2 (AUS)<\/li><\/ul>"},{"id":"268045-s-3-12","title":"Breast Feeding","mono":"Haemophilus B Vaccine: Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"268045-s-4","title":"Drug Interactions","sub":{"1":{"id":"268045-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"}}},"5":{"id":"268045-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction<\/li><li><b>Other:<\/b>Fever<\/li><\/ul>"},"6":{"id":"268045-s-6","title":"Drug Name Info","sub":{"0":{"id":"268045-s-6-17","title":"US Trade Names","mono":"<ul><li>ActHIB<\/li><li>Hibtiter<\/li><li>Pedvaxhib<\/li><li>Hiberix<\/li><\/ul>"},"2":{"id":"268045-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"268045-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"268045-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"268045-s-7","title":"Mechanism Of Action","mono":"Haemophilus b conjugate vaccine (meningococcal protein conjugate) is a polyribosylribitol phosphate (PRP) of Haemophilus influenza type b that is covalently bound to an outer membrane complex (OMPC) of Neisseria meningitidis serogroup B, which forms an antigen that stimulates antibody response and immunologic memory by converting the T-independent antigen into a T-dependent antigen.<br\/>"},"9":{"id":"268045-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IM use only; do not inject IV, intradermally, or subQ<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake well before use<\/li><li>inject into anterolateral aspect of the thigh or deltoid muscle; do not inject into the buttocks<\/li><li>ActHIB(R) reconstitute with 0.4% sodium chloride diluent; administer within 24 hours<\/li><li>Hiberix(R); reconstitute only with the supplied saline diluent; transfer the entire contents of the prefilled syringe of diluent into the vial of lyophilized vaccine; with the needle still inserted, vigorously shake; withdraw the entire contents of the vial (approximately 0.5 mL) back into the syringe for injection<\/li><li>Hiberix(R); administer promptly following reconstitution, or refrigerate and administer within 24 hours; if stored, shake vigorously again prior to administration<\/li><li>PedvaxHIB(R); ready to use; no dilution required<\/li><\/ul><\/li><\/ul>"},"11":{"id":"268045-s-11","title":"How Supplied","mono":"<ul><li><b>ActHIB<\/b><br\/>Intramuscular Powder for Solution: 10 MCG<br\/><\/li><li><b>Hiberix<\/b><br\/>Intramuscular Powder for Solution: 10 MCG<br\/><\/li><li><b>Pedvaxhib<\/b><br\/>Intramuscular Solution: 7.5 MCG\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"268045-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise caregiver that it may take up to 2 wks for the child to develop immunity.<\/li><li>This drug may cause an injection site reaction or fever.<\/li><li>Inform caregiver of the importance of the child receiving the entire series of vaccinations. If a dose is missed, another appointment should be scheduled as soon as possible.<\/li><\/ul>"}}}